Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder
ChiCTR1900025744Phase 4Recruiting
- Sponsor
- Department of Ophthalmology, PLA General Hospital
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Department of Ophthalmology, PLA General Hospital. Primary endpoints: Annual relapse rate, Best corrected visual acuity and 2 more. Started Sep 2019; status: recruiting.
02
Drugs
rituximab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR1900025744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025744.